TBPH

TBPH Operating Cash Flow (Statement)

$51.83MTTM · USD

Period ending:

TBPH FY Cash from OperationsUSD
TBPH FY Cash from Operations2011-12-31: -$83.43M2012-12-31: -$119.11M2013-12-31: -$120.96M2014-12-31: -$175.16M2015-12-31: -$168.86M2016-12-31: -$98.99M2017-12-31: -$201.05M2018-12-31: -$112.87M2019-12-31: -$238.20M2020-12-31: -$250.40M2021-12-31: -$207.86M2022-12-31: -$186.99M2023-12-31: -$27.00M2024-12-31: -$11.54M2025-12-31: $238.54M$238.54M-$250.40M
2011-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

TBPH operating cash flow (statement) history

Net cash provided by operating activities. The available annual fiscal periods series contains 15 observations from Dec 31, 2011 to Dec 31, 2025.

Theravance Biopharma Inc Operating Cash Flow (Statement) — Annual fiscal periods (USD)
Period endingOperating Cash Flow (Statement) (USD)
238,541,000
-11,535,000
-26,997,000
-186,991,000
-207,858,000
-250,403,000
-238,197,000
-112,867,000
-201,052,000
-98,989,000
-168,857,000
-175,155,000
-120,959,000
-119,107,000
-83,428,000

Compare operating cash flow (statement)

All TBPH financial metrics · TBPH stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.